Certara corrects misstatement on 2025 adjusted EBITDA for divested regulatory, medical writing unit
CERT•Correction to Q2 earnings call and presentation
Certara corrected a misstatement from its Aug. 4, 2026 Q2 earnings call on 2025 adjusted EBITDA from its divested Regulatory and Medical Writing unit.
- The call incorrectly cited about $17 million adjusted EBITDA excluding unallocated overhead; the $17 million figure includes unallocated overhead.
- Adjusted EBITDA excluding unallocated corporate expense that remains with the company was about $23 million.
- An updated earnings presentation replaced the version that carried the same error.
- The clarification does not change previously reported results or the 2026 financial outlook.
